Vasomedical Announces First Quarter 2014 Results

WESTBURY, N.Y., May 14, 2014 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO) today reported its operating results for the three months ended March 31, 2014.

"We are excited to report that during the quarter, the Company generated positive cash flow of $4.2 million from operating activities, mainly due to our VasoHealthcare subsidiary achieving the highest commission rate, which is applied retroactively for all orders booked in 2013," stated Jun Ma, President and CEO of Vasomedical. "As our GEHC business continues to grow, we are taking advantage of the higher cash inflows and reinvesting in our business, while continuing our search for opportunities to complement and diversify our business."

"While total revenues slightly declined by 3% to $7.1 million for the quarter, mainly due to a decrease in EECP equipment sales, we are optimistic that our international performance will improve once the recently announced cooperative agreement with PSK-Health Sci-Tech Development Co. Ltd., the leading manufacturer of ECP therapy systems in China, is implemented. This venture should help Vasomedical expand existing sales presence and tap into new geographical territories internationally, as well as substantially reduce sales and marketing costs.  We are currently in the process of reorganizing our EECP business model, both domestically and internationally, in view of this cooperative agreement."

"In addition, we strengthened our product portfolio within BIOX with the introduction of MobiCare™ system, a patented wireless multi-parameter patient monitoring system, and expect our China operations to grow. Looking forward, we believe we are well positioned to achieve profitability and maintain positive cash flow, and continue to achieve superior performance from our sales representation business," concluded Dr. Ma.

Three Months Ended March 31, 2014 Financial Results

For the three months ended March 31, 2014, revenue decreased by 3% to $7.1 million from $7.3 million for the same period of 2013. This is mainly attributable to a 45% decline in equipment sales due to decreased EECP^® revenues, which was partially offset by the 4% growth in commission revenues to $6.2 million, from our Sales Representation segment. As we have stated previously, EECP sales are expected to remain soft unless acceptance level for its currently indicated use and reimbursement policies change positively. The uncertain timing for this to occur was ultimately the reason behind the Company's diversification strategy, which included entering the GEHC representation agreement and acquiring its Chinese operating companies.     

Gross profit for the first quarter of 2014 increased 2% to $5.2 million, compared with $5.1 million for the first quarter of 2013.  This increase is primarily a result of the higher commission revenues from the Sales Representation segment, arising from higher commission rates for orders booked in 2013, partially offset by lower equipment shipments in the Equipment Segment.

Selling, general and administrative (SG&A) expenses for the first quarter of 2014 was $6.0 million or 85% of revenues, compared with $5.6 million, or 77% of revenues for the same period last year. This is mainly attributable to the annual sales team meeting in the Sales Representation segment during the quarter, which took place in the second quarter last year.    

Net loss for the three months ended March 31, 2014 was $1.0 million, a 60% increased loss compared with a net loss of $652,000 for the three months ended March 31, 2013, as a result of an 8% increase in selling, general and administrative costs.

Net cash increased by $4.0 million to $12.0 million at March 31, 2014, compared with net cash of $8.0 million as of December 31, 2013.  This increase in cash is mainly attributable to the significantly higher commission rate generated in the fourth quarter of 2013, resulting in significant cash inflows early in 2014.  Based on current forecast, we anticipate cash flow from operating activities to be positive for 2014. 

Deferred revenue remains substantial, at approximately $17.0 million as of March 31, 2014, to be recognized in the future when the underlying equipment is delivered and accepted at the customer site. 

Conference Call Information

The Company will host a conference call today at 10:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedical, and Michael Beecher, Chief Financial Officer of Vasomedical. To dial into the conference call, please dial 1-866-393-1344 from the U.S. or 1-631-291-4669, internationally. All dial-in participants must use the following code to access the call: 42076306. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical's website, www.vasomedical.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately two hours after completion of the live conference call at www.vasomedical.com. To access the dial-in replay of the call, which will be available until June 14, 2014, please dial 1-855-859-2056 or 1-404-537-3406. All dial-in participants must use the following code to access the call: 42076306.

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products.  The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP^® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain markets. Additional information is available on the Company's website at www.vasomedical.com.

(Tables to follow)

Summarized Financial Information

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: [email protected] / [email protected]

SOURCE Vasomedical, Inc.